Given that psychedelics micro-dosing has several commercial advantages, here are two companies that investors should look at.
Psychedelics
Eleusis Looks For Alzheimer’s Breakthrough With Micro-Dosed LSD
Eleusis Therapeutics is a private psychedelics company that is turning a lot of heads with its research on micro-doses of LSD as a treatment for Alzheimer's.
Mydecine Innovations Group Adds a Leading Neuroscientist and a Psychopharmacology Specialist
Mydecine's new Scientific Advisor will work directly with the CSO in new drug development initiatives.
COMPASS Pathways Strengthens Leadership Team With Appointment of Trevor Mill as Chief Development Officer
Compass appoints a new Chief Development Officer as part of several new appointments to its management team.
Canadians More Receptive To Use Of Psilocybin For The Terminally Ill: New Poll
Canadians are rapidly warming up to the idea of using psilocybin to reduce distress among the terminally ill.
ATAI launches IntroSpect Digital Therapeutics, Appoints veteran software engineer David Keene as CEO
ATAI is adding a digital therapeutics division to its R&D platform.
Numinus announces Clinical Advisory Council to advance its integrated wellness model
Numinus' new Clinical Advisory Council will provide support for its psychedelic drug R&D at all levels.
Red Light Holland Engages Former Health Minister, the Honourable, Tony P. Clement, as Senior Advisor to Advisory Board
Former Canada Health Minister joins Red Light Holland as Senior Advisor.
Champignon Provides Corporate Update, Announces Name Change, Rebranding and Planned Spin Out
Champignon Brands is proposing changing its corporate name to Apotheosis Scientific Ltd, and announces a planned spin-off its consumer packaged goods (CPG) division.
Wuhan General Group Signs Manufacturing, Distribution and Sales Agreement with Cafféluxe
Wuhan General lines up capsule manufacturer, specializing in coffee pods.
Mydecine Innovations Group Inc. Signs Partnership Agreement With Applied Pharmaceutical Innovation
Mydecine announces research agreement with a leading pharmacology research institution.
Osoyoos Announces Agreement to Acquire AI Pharmaceuticals Jamaica Limited
Osoyoos cannabis has acquired a psilocybin-focuse biopharma company based in Jamaica.
Mydecine Innovations Inks Important Research Agreement
Mydecine's research agreement with the University of Alberta is a key stepping-stone in expediting its psilocybin-based drug development research.
Mira X Acquisition Corp. Announces Proposed Qualifying Transaction with Field Trip Psychedelics Inc
Field Trip Psychedelics is planning to go public via a "three-cornered" RTO.
North Sur Resources and Mindset Pharma Announce Proposed Transaction to Accelerate Development of Medical Psychedelics Industry
An amalgamation of two private companies as psychedelics company Mindset Pharma Inc prepares to go public.